

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of the claims in the application.

1. (Currently amended) A fusion polypeptide comprising a first polypeptide operably linked to a second polypeptide,

wherein the first polypeptide comprises a polypeptide sequence with at least 85% homology to an extracellular portion of a glycoprotein Ib α polypeptide of SEQ ID NO:1, provided said glycoprotein Ib α polypeptide includes an amino acid other than glycine at position 233 or other than methionine at position 239 relative to the amino acid sequence of a wild-type GPIb α polypeptide, and said first polypeptide binds ~~a polypeptide selected from the group consisting of leukocyte integrin Mac-1 polypeptide, von Willebrand factor, thrombin and P-selectin;~~ and

wherein the second polypeptide comprises at least a region of an immunoglobulin heavy chain polypeptide.

2. (Cancelled)

3. (Previously presented) The fusion polypeptide of claim 1, wherein said first polypeptide binds to at least two of the polypeptides selected from the group consisting of leukocyte integrin Mac-1 polypeptide, von Willebrand factor, thrombin and P-selectin.

4. (Cancelled)

5. (Previously presented) The fusion polypeptide of claim 1, wherein said polypeptide comprises SEQ ID NO: 5.

6. (Previously presented) The fusion polypeptide of claim 1, wherein said fusion polypeptide is more resistant to proteolysis than a wild-type GP Iba polypeptide.

7. (Original) The fusion polypeptide of claim 1, wherein said first polypeptide binds with higher affinity to a von Willebrand factor polypeptide than a wild-type glycoprotein Iba polypeptide binds to said von Willebrand factor polypeptide.

8. (Original) The fusion polypeptide of claim 1, wherein said first polypeptide comprises at least one of the amino acid substitutions G233V or M239V relative to the amino acid sequence of a wild-type GPIba polypeptide.

9. (Previously presented) The fusion polypeptide of claim 1, wherein said first polypeptide comprises the amino acid substitutions G233V and M239V relative to the amino acid sequence of a wild-type GPIba polypeptide.

10. (Cancelled)

11. (Original) The fusion polypeptide of claim 1, wherein said second polypeptide comprises an Fc region of an immunoglobulin heavy chain.

12. (Original) The fusion polypeptide of claim 11, wherein said second polypeptide has less effector function than the effector function of a Fc region of a wild-type immunoglobulin heavy chain.

13. (Original) The fusion polypeptide of claim 12, wherein said second polypeptide binds with low or no affinity to a Fc receptor.

14. (Original) The fusion polypeptide of claim 12, wherein said second polypeptide binds with low or no affinity to complement protein C1q.

15-19. (Cancelled)

20. (Currently amended) The fusion polypeptide of claim 1, wherein said fusion polypeptide comprises the amino acid sequence of GPIIb α 302/4X-Ig (SEQ ID NO:3), or GPIIb α 290/2V-Ig (SEQ ID NO:5).

21. (Original) A multimeric polypeptide comprising the fusion polypeptide of claim 1.

22. (Original) The multimeric polypeptide of claim 21, wherein said multimeric polypeptide is a dimer.

23-26. (Cancelled)

27. (Original) A pharmaceutical composition comprising the fusion polypeptide of claim 1.

28-53. (Cancelled)

54. (Previously presented) The fusion polypeptide of claim 1, wherein said first polypeptide binds at least three polypeptides selected from the group consisting of leukocyte integrin Mac-1 polypeptide, von Willebrand factor, thrombin and P-selectin.

55. (previously presented) The fusion polypeptide of claim 1, wherein said first polypeptide binds leukocyte integrin Mac-1 polypeptide, von Willebrand factor, thrombin and P-selectin.

56. (Previously presented) The fusion polypeptide of claim 1, wherein said first polypeptide binds leukocyte integrin Mac-1 polypeptide.

57. (Cancelled)

58. (Previously presented) The fusion polypeptide of claim 1, wherein said first polypeptide binds thrombin.

59. (Previously presented) The fusion polypeptide of claim 1, wherein said first polypeptide binds P-selectin.

60. (Previously presented) A fusion polypeptide comprising a first polypeptide operably linked to a second polypeptide,

wherein the first polypeptide consists essentially of a polypeptide sequence with at least 85% homology to an extracellular portion of a glycoprotein Ib α polypeptide of SEQ ID NO:1, provided said glycoprotein Ib α polypeptide includes an amino acid other than glycine at position 233 or other than methionine at position 239 relative to the amino acid sequence of a wild-type GPIb α polypeptide and said first polypeptide binds von Willebrand factor polypeptide; and

wherein the second polypeptide consists essentially of an immunoglobulin heavy chain polypeptide, wherein said immunoglobulin heavy chain polypeptide comprises a Fc region.

61-62. (Cancelled)

63. (Previously presented) A polypeptide consisting essentially of the amino acid sequence of SEQ ID NO:1.

64. (Previously presented) The polypeptide of claim 63, wherein the amino acid sequence of the polypeptide consists of SEQ ID NO:1.

65. (Previously presented) A polypeptide consisting essentially of the amino acid sequence of SEQ ID NO:5.

66. (Previously presented) The polypeptide of claim 65, wherein the amino acid sequence of the polypeptide consists of SEQ ID NO:5.